A randomized trial found improved self-reported executive functioning when lisdexamfetamine was added to stable antidepressant treatment in selected adults. The primary result was a questionnaire benefit, not a direct demonstration of restored performance in every daily activity.
The study randomized 143 adults with partially or fully remitted major depressive disorder and persistent executive complaints to nine weeks of lisdexamfetamine or placebo augmentation. Participants remained on stable antidepressant monotherapy. The primary endpoint was change in the BRIEF-A self-report Global Executive Composite. One hundred nineteen participants completed the double-blind period.
The adjusted difference in the primary questionnaire outcome favored lisdexamfetamine by eight T-score points, with a confidence interval excluding no difference. Depressive-symptom ratings also showed a smaller favorable comparison. Adverse events were reported in both groups and were somewhat more frequent with active treatment. These findings concern augmentation in a selected clinical context rather than stand-alone treatment of untreated depression.
The authors noted that perceiving stimulant effects might influence self-reports even without formally breaking the blind. Questionnaire changes may reflect everyday experience, but they are not interchangeable with laboratory cognitive testing, work performance or independent functional assessment. Nine weeks also cannot establish long-term benefit or safety. The study does not support generalizing to every person with depression, replacing an antidepressant or assuming an amphetamine response identifies a diagnosis. Its contribution is a positive controlled symptom outcome that warrants a clear account of the measurement method, population and follow-up limits. No individual impairment or drug-concentration rule follows from it.
See why a treatment’s clinical context matters.